Stock Scorer

TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics, Inc. reported revenue of 1.1M USD for the quarter ending 30 June 2026, down 65.8% from 3.1M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 1.1M -65.8%
Operating Income Q2 '26 · ending 30 June 2026 -30.5M —
Net Income Q2 '26 · ending 30 June 2026 -30.4M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -27.5M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -28M —
Shares Outstanding Q2 '26 · ending 30 June 2026 129.9M +0.2%
EPS Q2 '26 · ending 30 June 2026 -0.91 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 10.3M-135.8M-129.8M-139.7M
20242024-12-31 2.8M-134.8M-127.5M-114.6M
20232023-12-31 21M-93.5M-89.2M-64.5M
20222022-12-31 13.5M-66.6M-66.2M-70.7M
20212021-12-31 10.1M-48.6M-48.6M-58.6M
20202020-12-31 1.1M-26.2M-26.1M-7.3M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-301.1M
Q1 '262026-03-31982K
Q4 '252025-12-312.6M
Q3 '252025-09-302.5M
Q2 '252025-06-303.1M
Q1 '252025-03-312.2M
Q4 '242024-12-31665K
Q3 '242024-09-301M
Q2 '242024-06-30536K
Q1 '242024-03-31566K
Q4 '232023-12-317.2M
Q3 '232023-09-303.9M
Q2 '232023-06-303.1M
Q1 '232023-03-316.8M
Q4 '222022-12-313.1M
Q3 '222022-09-303.4M
Q2 '222022-06-304.1M
Q1 '222022-03-313M
Q4 '212021-12-312.9M
Q3 '212021-09-302.4M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-30.5M
Q1 '262026-03-31-29.1M
Q4 '252025-12-31-23.9M
Q3 '252025-09-30-37.1M
Q2 '252025-06-30-38.7M
Q1 '252025-03-31-36.2M
Q4 '242024-12-31-36.7M
Q3 '242024-09-30-32.6M
Q2 '242024-06-30-34.1M
Q1 '242024-03-31-31.4M
Q4 '232023-12-31-21.4M
Q3 '232023-09-30-24.7M
Q2 '232023-06-30-24.6M
Q1 '232023-03-31-22.7M
Q4 '222022-12-31-18.6M
Q3 '222022-09-30-16.6M
Q2 '222022-06-30-15.2M
Q1 '222022-03-31-16.2M
Q4 '212021-12-31-14.2M
Q3 '212021-09-30-15.8M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-30.4M
Q1 '262026-03-31-28.7M
Q4 '252025-12-31-23M
Q3 '252025-09-30-35.7M
Q2 '252025-06-30-37M
Q1 '252025-03-31-34.1M
Q4 '242024-12-31-35.8M
Q3 '242024-09-30-29.9M
Q2 '242024-06-30-31.7M
Q1 '242024-03-31-30.1M
Q4 '232023-12-31-19.6M
Q3 '232023-09-30-23M
Q2 '232023-06-30-24M
Q1 '232023-03-31-22.6M
Q4 '222022-12-31-18.7M
Q3 '222022-09-30-16.2M
Q2 '222022-06-30-15.1M
Q1 '222022-03-31-16.2M
Q4 '212021-12-31-14.2M
Q3 '212021-09-30-15.8M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-27.5M
Q1 '262026-03-31-24.3M
Q4 '252025-12-31-32M
Q3 '252025-09-30-32.5M
Q2 '252025-06-30-33.3M
Q1 '252025-03-31-37.6M
Q4 '242024-12-31-27.4M
Q3 '242024-09-30-27.9M
Q2 '242024-06-30-26.2M
Q1 '242024-03-31-29.3M
Q4 '232023-12-31-23.8M
Q3 '232023-09-308M
Q2 '232023-06-30-22M
Q1 '232023-03-31-23.6M
Q4 '222022-12-31-16M
Q3 '222022-09-30-17M
Q2 '222022-06-30-13.4M
Q1 '222022-03-31-20.1M
Q4 '212021-12-31-14.4M
Q3 '212021-09-30-13.6M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-28M
Q1 '262026-03-31-24.3M
Q4 '252025-12-31-32.2M
Q3 '252025-09-30-33.9M
Q2 '252025-06-30-34.5M
Q1 '252025-03-31-39.1M
Q4 '242024-12-31-28.3M
Q3 '242024-09-30-29.3M
Q2 '242024-06-30-27.1M
Q1 '242024-03-31-30M
Q4 '232023-12-31-24.2M
Q3 '232023-09-306.6M
Q2 '232023-06-30-22.4M
Q1 '232023-03-31-24.4M
Q4 '222022-12-31-17.4M
Q3 '222022-09-30-17.4M
Q2 '222022-06-30-15.3M
Q1 '222022-03-31-20.7M
Q4 '212021-12-31-16.6M
Q3 '212021-09-30-14.5M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30129.9M
Q1 '262026-03-31129.9M
Q3 '252025-09-30129.8M
Q2 '252025-06-30129.7M
Q1 '252025-03-31129.7M
Q3 '242024-09-30118.7M
Q2 '242024-06-30113.4M
Q1 '242024-03-3194.9M
Q3 '232023-09-3094.8M
Q2 '232023-06-3047.2M
Q1 '232023-03-3124.2M
Q3 '222022-09-3024.1M
Q2 '222022-06-3024.1M
Q1 '222022-03-3124M
Q3 '212021-09-3019.9M
Q2 '212021-06-301.4M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-0.91
Q1 '262026-03-31-0.96
Q4 '252025-12-31-1.00
Q3 '252025-09-30-1.12
Q2 '252025-06-30-1.09
Q1 '252025-03-31-1.09
Q4 '242024-12-31-1.15
Q3 '242024-09-30-0.96
Q2 '242024-06-30-0.95
Q1 '242024-03-31-1.18
Q4 '232023-12-31-1.79
Q3 '232023-09-30-2.45
Q2 '232023-06-30-2.88
Q1 '232023-03-31-3.00
Q4 '222022-12-31-2.74
Q3 '222022-09-308.84
Q2 '222022-06-308.71
Q1 '222022-03-311.65
Q4 '212021-12-31-4.17
Q3 '212021-09-30-23.06